Perspective
Caging cancer

https://doi.org/10.1016/j.nano.2015.02.005Get rights and content

Abstract

This article summarizes the overall issues surrounding cancer for the general audience. Individual differences between patients include genetic and non-genetic differences manifested in various cellular pathways, tumor heterogeneity and variability, differing contribution of tumor microenvironment and potential toward metastasis. Successful treatment of individuals depends on correctly interpreting all these factors and appropriately addressing the actual features by using customized therapy strategies, simultaneously or sequentially. Currently used chemotherapy agents are cytotoxic and typically target one of the major pathways; therefore they have to be applied in combination regimes. Nanomedicines however, have the potential advantage that more than one feature can be built into a complex nanodevice. This yet untapped potential is illustrated on the example of a gadolinium fullerenol cage molecule. Gd@C82(OH)22 has low toxicity, influences several biologic features simultaneously, displays tumoristatic properties, and is effective against triple-negative breast cancer cells. A deeper understanding of the exact relations between the physicochemical characteristics of this system and the biologic events may lead to a new class of efficient anticancer pharmaceutics.

From the Clinical Editor

The search for the magic bullet in the treatment of cancer has long been the dream of clinicians and researchers worldwide. Inherent cellular characteristics of cancer cells have made this task extremely hard to reach. In this article, the author provided a concise summary on the understanding and challenges in the current battle and also illustrated the potential usefulness of the recently developed gadolinium fullerenol cage molecule by describing experimental data from various research groups.

References (28)

  • B. Brucher et al.

    Epistemology of the origin of cancer: a new paradigm

    BMC Cancer

    (2014)
  • T. Lapidot et al.

    A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

    Nature

    (1994)
  • H. Korkaya et al.

    Cancer stem cells: nature versus nurture

    Nat Cell Biol

    (2010)
  • W. Yasui et al.

    Cancer stem cells

    Cancer Sci

    (2007)
  • Cited by (14)

    • Therapeutic targets in the selective killing of cancer cells by nanomaterials

      2017, Clinica Chimica Acta
      Citation Excerpt :

      NMs composed of cobalt oxide, on the other hand, induced greater toxicity in BEAS-2B cells that originated from normal tissue, but the toxicity was negligible in A549 cells that originated from cancerous tissue [161]. A deeper understanding of the exact relations between the physicochemical characteristics of the NMs and the biologic events may lead to a new class of effective anticancer pharmaceutics [162]. A better understanding of the biochemical features of cancer and our ability to predict NM-induced bio-responses would facilitate the engineering of NMs with desired bio-physicochemical properties that might be more efficient in achieving selectivity in the killing of cancer cells while not affecting normal cells.

    • Fullerenols: Physicochemical properties and applications

      2016, Progress in Solid State Chemistry
      Citation Excerpt :

      However, further research on toxicity, biodistribution, and biodegradation of fullerenols is needed. In order to obtain mоre detailed information on biomedical applications of fullerenol and other water-soluble fullerene derivatives, the interested reader is referred to several in-depth studies [85,86,111–113]. The possible applications of fullerenols in bionanomedicine are summarized in Fig. 16.

    • Biological interactions of carbon-based nanomaterials: From coronation to degradation

      2016, Nanomedicine: Nanotechnology, Biology, and Medicine
      Citation Excerpt :

      In particular, gadolinium (Gd) based metallofullerenes are developed as innovative contrast agents, and may also act as anti-cancer agents.46 For example, the multi-hydroxylated metallofullerenol Gd@C82(OH)22 was recently shown to inhibit tumor metastasis through MMP inhibition rather than through direct killing of the cancer cells,47 thus suggesting a new, nanomedicine-based approach in the management of tumor metastasis.48 In subsequent studies, based on computational and experimental approaches, the authors proposed that Gd@C82(OH)22 suppress pancreatic cancer metastasis by inhibiting the interaction of histone deacetylase 1 (HDAC1) and metastasis-associated protein 1 (MTA1), thus acting as a novel HDAC inhibitor.49

    View all citing articles on Scopus
    View full text